US Stock MarketDetailed Quotes
ARTL Artelo Biosciences
- 1.3600
- +0.0399+3.02%
Close May 16 16:00 ET
4.39MMarket Cap-430P/E (TTM)
1.3600High1.3200Low1.97KVolume1.3200Open1.3201Pre Close2.62KTurnover0.06%Turnover RatioLossP/E (Static)3.23MShares2.980052wk High0.46P/B4.35MFloat Cap1.150052wk Low--Dividend TTM3.20MShs Float75.0000Historical High--Div YieldTTM3.03%Amplitude1.1500Historical Low1.3310Avg Price1Lot Size
About Artelo Biosciences Company
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
Company Profile
SymbolARTL
Company NameArtelo Biosciences
Listing DateJun 21, 2019
Founded2011
CEOMr. Gregory D. Gorgas
MarketNASDAQ
Employees6
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address505 Lomas Santa Fe,Suite 160
CitySolana Beach
ProvinceCalifornia
CountryUnited States of America
Zip Code92075
Phone1-858-925-7049
Websitehttp://www.artelobio.com
Company Executives
- Name
- Position
- Salary
- Gregory D. Gorgas
- Director, President, Chief Executive Officer, Secretary, Chief Financial Officer, Principal Accounting Officer and Treasurer
- 654.83K
- Connie L. Matsui
- Chairman of the Board
- 69.54K
- Steven Kelly
- Independent Director
- 52.54K
- R. Martin Emanuele, PhD
- Independent Director
- 37.04K
- Gregory R. Reyes
- Independent Director
- 37.04K
- Tamara A. Favorito
- Independent Director
- 48.04K
- Dr. Douglas Blayney, M.D.
- Independent Director
- 41.04K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg